[Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
Chemotherapy results for all 157 patients with advanced/recurrent gastric cancer at our institute were analyzed based on survival duration. The median survival time (MST) of all 157 patients was 426 days. The break down of the 157 patients are as follows: 59 patients with recurrence after curative operation, 47 patients with a radical grade C after non-curative operation and 51 patients with unresectable gastric cancer, and whose MST's were 590, 610 and 215 days, respectively. The standard chemotherapy for advanced/recurrent gastric cancer has not been established. Our data showed that chemotherapy for gastric cancer should be performed as a means of clinical study. If the patients had any exclusion criteria of clinical study or a proper clinical study did not exist, we would have recommended the TS-1 based regimen as the first-line chemotherapy, and the taxane based regimen as the second-line chemotherapy.